At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OMER Omeros
Market Closed 12-20 16:00:00 EST
10.31
+0.07
+0.68%
盘后10.27
-0.04-0.39%
19:32 EST
High12.83Low10.08Vol2.51M
Open10.08D1 Closing10.24Amplitude26.86%
Mkt Cap597.46MTradable Cap570.90MTotal Shares57.95M
T/O28.12MT/O Rate4.53%Tradable Shares55.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Sector Update: Health Care Stocks Lower Thursday Afternoon
MT Newswires Live  ·  12-20
Sector Update: Health Care Stocks Lower Thursday Afternoon
Omeros Stock Gains 52% On Successful Trial Results
Dow Jones  ·  12-19
Omeros Stock Gains 52% On Successful Trial Results
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges
GuruFocus.com  ·  12-19
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges
Omeros Up Over 66%, On Track for Highest Close Since September 2021 -- Data Talk
Dow Jones  ·  12-19
Omeros Up Over 66%, On Track for Highest Close Since September 2021 -- Data Talk
Omeros' Pivotal Trial of Narsoplimab Meets Primary Endpoint
MT Newswires Live  ·  12-19
Omeros' Pivotal Trial of Narsoplimab Meets Primary Endpoint
Omeros announces narsoplimab trial meets primary endpoint
TIPRANKS  ·  12-19
Omeros announces narsoplimab trial meets primary endpoint
Omeros Corp: to Resubmit a Bla to FDA for Narsoplimab
THOMSON REUTERS  ·  12-19
Omeros Corp: to Resubmit a Bla to FDA for Narsoplimab
Omeros' Narsoplimab Meets Its Pivotal Trial Primary Endpoint
THOMSON REUTERS  ·  12-19
Omeros' Narsoplimab Meets Its Pivotal Trial Primary Endpoint
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Business Wire  ·  12-19
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges
Insider Monkey  ·  12-11
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
Business Wire  ·  12-10
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
Business Wire  ·  12-02
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News
GuruFocus  ·  11-23
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News
Omeros surges 22% on clarity for BLA resubmission for narsoplimab
seekingalpha  ·  11-23
Omeros surges 22% on clarity for BLA resubmission for narsoplimab
BRIEF-Omeros Provides Update On Progress Toward BLA Resubmission For Narsoplimab
Reuters  ·  11-21
BRIEF-Omeros Provides Update On Progress Toward BLA Resubmission For Narsoplimab
Rpt-Omeros Corp - Independent Expert Statistical Group to Conduct Analyses
THOMSON REUTERS  ·  11-21
Rpt-Omeros Corp - Independent Expert Statistical Group to Conduct Analyses
Rpt-Omeros Corp - Receives FDA Response on Revised Sap for Narsoplimab Bla
THOMSON REUTERS  ·  11-21
Rpt-Omeros Corp - Receives FDA Response on Revised Sap for Narsoplimab Bla
Rpt-Omeros Corporation Provides Update on Progress Toward Bla Resubmission
THOMSON REUTERS  ·  11-21
Rpt-Omeros Corporation Provides Update on Progress Toward Bla Resubmission
Corrected-Omeros Corp - FDA Had Previously Requested Additional Sensitivity Analyses for Sap (Adds Dropped Words 'Had Previously Requested')
THOMSON REUTERS  ·  11-21
Corrected-Omeros Corp - FDA Had Previously Requested Additional Sensitivity Analyses for Sap (Adds Dropped Words 'Had Previously Requested')
Omeros provides update on narsoplimab BLA resubmission
TIPRANKS  ·  11-21
Omeros provides update on narsoplimab BLA resubmission

Introduction

Company Name.
Omeros
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Issue price:
--